IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.998
NA - Nord America 3.946
AS - Asia 671
SA - Sud America 179
AF - Africa 21
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.818
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.919
GB - Regno Unito 955
IE - Irlanda 737
IT - Italia 677
SE - Svezia 350
DE - Germania 308
RU - Federazione Russa 295
SG - Singapore 294
CN - Cina 236
FR - Francia 220
BR - Brasile 163
UA - Ucraina 158
FI - Finlandia 122
ES - Italia 49
BE - Belgio 31
IN - India 25
HK - Hong Kong 24
VN - Vietnam 24
AT - Austria 17
NL - Olanda 16
CA - Canada 14
TR - Turchia 14
CZ - Repubblica Ceca 12
CI - Costa d'Avorio 8
IR - Iran 8
AR - Argentina 7
GR - Grecia 7
DK - Danimarca 6
EE - Estonia 6
JP - Giappone 6
MX - Messico 6
LV - Lettonia 5
EG - Egitto 4
PL - Polonia 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
GE - Georgia 3
IQ - Iraq 3
KR - Corea 3
LK - Sri Lanka 3
LT - Lituania 3
PA - Panama 3
PE - Perù 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BG - Bulgaria 2
BO - Bolivia 2
BW - Botswana 2
CH - Svizzera 2
ID - Indonesia 2
IL - Israele 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MA - Marocco 2
NP - Nepal 2
TH - Thailandia 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BY - Bielorussia 1
CL - Cile 1
CY - Cipro 1
EC - Ecuador 1
EU - Europa 1
HU - Ungheria 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
MD - Moldavia 1
NO - Norvegia 1
PK - Pakistan 1
PY - Paraguay 1
RO - Romania 1
TM - Turkmenistan 1
TN - Tunisia 1
UY - Uruguay 1
Totale 8.818
Salva come PNG Salva come JPEG
Città #
Southend 848
Dublin 730
Fairfield 529
Chandler 443
Santa Clara 340
Siena 232
Woodbridge 225
Ashburn 222
Ann Arbor 216
Seattle 213
Houston 188
Cambridge 187
Wilmington 166
Singapore 142
Munich 141
Jacksonville 127
Princeton 117
Helsinki 84
New York 73
Beijing 61
Milan 54
Rome 53
Málaga 44
Boardman 42
San Diego 41
San Mateo 38
Shanghai 36
Brussels 31
Nanjing 29
Portsmouth 29
Florence 27
Los Angeles 26
Moscow 24
Dong Ket 22
Dearborn 21
Council Bluffs 20
Hong Kong 20
Lauterbourg 20
London 20
Düsseldorf 16
Frankfurt am Main 16
Nanchang 16
Fremont 15
Nuremberg 15
Dallas 11
Redwood City 11
São Paulo 11
Vienna 11
Brescia 10
Changsha 10
Norwalk 10
Toronto 10
Belo Horizonte 9
Guangzhou 9
Newark 9
Perugia 9
The Dalles 9
Abidjan 8
Lappeenranta 8
Menlo Park 8
Roccagorga 8
Tianjin 8
Brno 7
Kunming 7
Naples 7
Paris 7
Columbus 6
Izmir 6
Jiaxing 6
Lograto 6
Ningbo 6
Padova 6
Chicago 5
Falkenstein 5
Hebei 5
Jinan 5
Leawood 5
North Bergen 5
Riga 5
Rio de Janeiro 5
San Francisco 5
Andover 4
Brasília 4
Caivano 4
Espoo 4
Jyväskylä 4
Leipzig 4
Mumbai 4
Pavia 4
Porto Alegre 4
Prague 4
Redmond 4
Saint-Fons 4
Shenyang 4
Tallinn 4
Taranto 4
Turin 4
Venezia 4
Washington 4
Zanjan 4
Totale 6.313
Salva come PNG Salva come JPEG
Nome #
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 264
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 231
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 215
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 205
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 185
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 181
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 180
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 178
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 177
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 171
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 169
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 168
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 167
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 167
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 165
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 162
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 161
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 159
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 157
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 152
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 150
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 144
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 143
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 143
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 133
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 132
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 127
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 127
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 127
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 125
null 121
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 118
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 117
null 114
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 112
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 112
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 109
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 107
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 103
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 103
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 102
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 100
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 99
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 98
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 98
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 98
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 97
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 92
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 89
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 85
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 76
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 75
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 75
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 74
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 72
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 71
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 71
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 71
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 70
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 69
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 66
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 65
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 59
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 57
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 57
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 56
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 55
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 51
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 50
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 50
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 49
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 49
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 46
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 44
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 44
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 43
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 43
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 41
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 41
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 40
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 37
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 34
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 34
null 32
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 30
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 30
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 28
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 23
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 19
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 18
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 16
null 14
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 13
null 12
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 8
Totale 9.117
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.303
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020105 0 0 0 0 0 0 0 0 0 0 31 74
2020/20211.220 49 84 26 177 122 138 114 141 112 103 69 85
2021/20221.238 69 136 92 161 66 65 71 71 69 109 110 219
2022/20231.426 78 204 166 164 126 270 69 100 97 61 63 28
2023/20241.197 38 36 101 77 21 307 408 35 8 26 34 106
2024/20252.099 67 99 377 183 288 231 110 207 319 158 60 0
Totale 9.117